Pheburane will be funded from the 1st December 2019 for the treatment of Urea Cycle Disorders
Pheburane Listed on the Pharmaceutical Benefits Scheme
MELBOURNE, Australia, December 1st, 2019 – Orpharma Pty Ltd. and Lucane Pharma SA. are pleased to announce the listing of Pheburane on the Pharmaceutical Benefits Scheme (PBS). Pheburane will be funded from the 1st December 2019 for the treatment of Urea Cycle Disorders (UCDs).
Pheburane was approved by Australia’s TGA in May 2017 for the treatment of UCDs. Listing on the PBS will make the product readily available to all patients diagnosed with the condition. The Product Information can be accessed here. The Consumer Medicine Information can be accessed here.
Pheburane is an improved formulation of Sodium Phenylbutyrate, a standard treatment for UCD patients to remove ammonia. Sodium phenylbutyrate has a very strong bitter and salty taste which may compromise compliance to treatment, especially in children. Pheburane offers a formulation where the taste is completely masked.